Effects of erythromycin on chemoattractant-activated human polymorphonuclear leukocytes.
1. Erythromycin (2-100 micrograms ml-1) produced a concentration-related inhibition of superoxide generation and elastase release induced by in vitro exposure of human polymorphonuclear leukocytes (PMNs) to the chemotactic peptide N-formylmethionyl-leucyl-phenylalanine (FMLP; 30 nM). 2. By contrast, erythromycin (100 micrograms ml-1) did not alter the leukotriene B4 production elicited by FMLP (30 nM; in the presence of thimerosal 20 microM) or the intracellular calcium changes promoted by FMLP (30 nM; in the absence or presence of thimerosal 20 microM). 3. These results indicate that by reducing chemoattractant-triggered release of oxidative and proteolytic mediators from human PMNs, erythromycin may have clinically useful antiinflammatory effects.
Villagrasa
V
V
Department of Pharmacology, College of Medicine and Dentistry, Valencia University, Spain.
Berto
L
L
Cortijo
J
J
Perpina
M
M
Sanz
C
C
Morcillo
E J
EJ
D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002118:Calcium / Q000097:blood; D002630:Chemotactic Factors / Q000494:pharmacology*; D004917:Erythromycin / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D019272:Leukocyte Elastase / Q000097:blood; D007975:Leukotriene B4 / Q000097:blood; D008163:Luminescent Measurements; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology*; D009504:Neutrophils / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D013481:Superoxides / Q000097:blood; D013849:Thimerosal / Q000494:pharmacology
D000893:Anti-Inflammatory Agents; D002630:Chemotactic Factors; D013481:Superoxides; D007975:Leukotriene B4; D013849:Thimerosal; D009240:N-Formylmethionine Leucyl-Phenylalanine; D004917:Erythromycin; D019272:Leukocyte Elastase; D002118:Calcium